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response in part II and III (p = 0.0078 and p = 0.0072, respectively). a trend to better 
results for the LCE group was observed in part I and IV. CONCLUSIONS: Levodopa/
carbidopa/entacapone shows a signiﬁ cant better patient and physician global percep-
tion in the LCE treatment group vs. LC group in PD patients with early WO and 
ADLs deterioration.
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OBJECTIVES: Since its development in the 80’s, variations of the Alzheimer’s Disease 
Assessment Scale-Cognitive subscale (ADAS-Cog), a Clinician-Reported Outcome 
(ClinRO) measure, have been used to monitor disease progression and treatment 
efﬁ cacy in Alzheimer’s disease. The objective of this study was to identify all versions 
used as a basis for translation in Mapi Institute projects and to take stock of existing 
translations. METHODS: The review was based on all ADAS-Cog translation projects 
performed by Mapi Institute. RESULTS: Sixteen projects were identiﬁ ed representing 
a total of 70 languages and 219 translations. Translations were based on 11 source 
versions which differed in terms of content (number of items, order of items and 
instructions), and format. The number of items ranged from 11 to 15. Four studies 
used 13 items, but only in two cases the same items were used although in a different 
order. Four studies used 12 items: only two studies used the same items (with a dif-
ferent list of words for the Word Recognition Task), but again in a different order. 
Format and instructions differed in all cases. In most projects the source version 
provided by the sponsor was a single document mixing instructions with the rater and 
response forms. Only in 3 cases the original consisted in a separate instruction manual 
and response forms. With regard to available translations, more than one translation 
was identiﬁ ed in 56 of the 70 available languages and in one language (Swedish) as 
many as 7 translations. CONCLUSIONS: The abundance of different versions of the 
same questionnaire both in its original US English form as in translations makes 
comparisons between studies or pooling of data difﬁ cult for both researchers and 
users. In the light of FDA’s recent PRO guidance it would be beneﬁ cial to demand 
the same scientiﬁ c rigor when using ClinROs in international studies.
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OBJECTIVES: Quality of life (QoL) is an important measure that is often overlooked 
in the assessment of multiple sclerosis (MS). The MS International QoL (MusiQoL) 
questionnaire is a validated, MS-speciﬁ c instrument. This study aimed to assess the 
responsiveness of the MusiQoL questionnaire to changes in Expanded Disability 
Status Scale (EDSS) scores in patients with MS. METHODS: In this ongoing, 
24-month, multicentre, observational study, MusiQoL and EDSS scores were recorded 
at baseline (BL) and at 6-month intervals. The primary endpoint is change in MusiQoL 
index score from BL to month 24 (including effect size). Secondary endpoints include 
change in MusiQoL index score from BL to month 12 and change in MusiQoL scale 
scores. RESULTS: Of 600 patients enrolled, 474 had evaluable BL and month-12 
EDSS and MusiQoL index data. At BL, mean (SD) EDSS score was 2.9 (1.9); mean 
(SD) MusiQoL index score was 68.5 (14.4); and mean (SD) MusiQoL scale scores 
ranged from 59.9 (24.8) to 85.4 (18.5). At month 12, 68 patients (14.3%) had a worse 
EDSS score than that recorded at BL. Mean (SD) change in MusiQoL index score was 
0.48 (10.99) overall, and −1.00 (9.88) in “worsened” patients; effect sizes were 0.03 
and −0.08, respectively. Changes from BL to month 12 in MusiQoL scale scores were 
mostly small. However, there were larger (mean [SD]) decreases in some subscales at 
month 12 for “worsened” patients: “Activities-of-daily-living” (−4.20 [18.07]); “Rela-
tionship-with-family” (−5.14 [23.43]); ‘Sentimental-and-sexual-life’ (−4.11 [17.56]); 
and ‘Relationship-with-health care-system’ (−3.56 [14.11]). Effect sizes were −0.17, 
−0.25, −0.14 and −0.21 respectively. Conversely, the mean (SD) change in ‘Symptoms’ 
score was 5.36 (17.27) at month 12 for ‘worsened’ patients (effect size: 0.24). CON-
CLUSIONS: As expected, most MusiQoL scores decreased over 12 months in patients 
with worsening EDSS scores, indicating poorer QoL and conﬁ rming the utility of the 
MS-speciﬁ c MusiQoL in rating QoL.
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OBJECTIVES: Huntington’s disease (HD) is a rare neurodegenerative disease leading 
to sustained disability for patients and poor quality of life (QoL) for patients as well 
as caregivers. This study investigated the impact of HD on caregivers’ QoL and its 
drivers. METHODS: The European HD burden study (Euro-HDB) is an ongoing 
cross-sectional survey among HR patients and their caregivers in six countries (France, 
Italy, Germany, UK, Sweden and Spain). The Huntington’s disease Quality of Life 
Battery for Carers (HDQoL-C) short-version, a previously validated questionnaire by 
Aubeeluck A. and Buchanan H., was administered. Pearson correlations with generic 
HR-QOL (SF36, EQ5D) and the speciﬁ c HR-QOL in HD for patients (HQOLI) were 
evaluated. The determinants of caregiver QOL among drivers among patients’ clinical 
characteristics (voluntary movement disorders, chorea, depression/anxiety, psychotic 
disorder, cognition, temper) were studied by regression analysis adjusting on age, sex 
and occupational categories. The relationship between QOL of patients and caregivers 
were also explored. RESULTS: To date, 201 caregivers in France and 124 in Italy 
have been enrolled. For France (respectively Italy) 6% (12%) were completely unsatis-
ﬁ ed by their overall QOL and 7% (5%) were totally satisﬁ ed. HDQoL-C scores were 
poorly correlated with generic caregiver HR-QOL: correlation equaled 0.31 for EQ5D 
utility and varied between 0.04 and 0.45 for the eight domains of SF36. Correlation 
was quite high (0.59; P < 0.01) between HDQoL-C and HQOLI. Drivers of caregiver’s 
QoL were voluntary movement disorders (p = 0.049), depression/anxiety (p = 0.02), 
psychotic disorder (p = 0.01) and cognition (p = 0.01). Temper and chorea were not 
drivers of caregivers’ QOL independently of other clinical characteristics. CONCLU-
SIONS: Caregivers QOL worsens as the patient clinical characteristics deteriorate 
especially voluntary movement disorders, depression/anxiety, psychotic disorders and 
cognition disorders. Patients and caregiver QoL was indirectly correlated via patient 
clinical scores. The potential impact on caregiver QOL should be considered in evalu-
ations of innovative HD treatments.
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OBJECTIVES: This study assesses, for an estimated EU pain population of 50 million 
patients, the impact of pain severity and frequency on three dimensions of health 
related quality of life (HRQoL): the SF-12 MCS and PCS scores and (ii) the SF-6D 
absolute utility scores. METHODS: The study is based on data from the internet based 
2008 National Health and Wellness Survey undertaken in the UK, France, Spain, 
Germany and Italy. This study identiﬁ ed 11,000 respondents (1 in 5 of the estimated 
big 5 EU countries) who had experienced pain in the last month. The assessment of 
the quantitative impact of pain status on HRQoL is estimated via three single equation 
generalized linear (ordinary least squares) models which estimate the impact of pain 
on PCS, MCS and utility scores. The model includes a range of variables which have 
been shown in previous population studies to impact HRQoL. These include: socio-
demographic factors, health risk behaviors, comorbidity status, medication utilization, 
duration of medication utilization and satisfaction with care. The experience of pain 
is captured by a combination of severity and frequency categorical variables. 
RESULTS: Pain has a substantial impact on all three of the dimensions of HRQoL 
considered here. Compared to the reference category (mild pain experienced weekly 
or less) the presence of severe, daily pain has a substantial impact on SF-12 PCS scores 
(−13.85 points); SF-12 MCS scores (−4.72); and SF-6D utilities (−0.147). There is a 
marked gradient on scores by severity and frequency of pain experience. The impact 
of pain on HRQoL is more signiﬁ cant than the impact of socio-demographic charac-
teristics, health risk factors, comorbidities and the experience of pain medication. 
CONCLUSIONS: The presence of moderate and severe pain imposes a signiﬁ cant 
burden on persons reporting pain in the big 5 EU countries; the burden increases the 
greater the frequency and severity.
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OBJECTIVES: The aim of the study was to survey some objective and subjective 
indicators determining the quality of life of people with Down’s syndrome (DS), born 
between 1975 and 2005, looked after in their families in the Southern-Transdanubian 
region of Hungary. The relationship between the parental level of education and the 
above factors was explored. METHODS: On the basis of the VRONY database 
(National Registry of Congenital Anomalies) health visitors contacted families looking 
after DS people (N = 107), and conducted anonymous, questionnaire surveys in 
2008–2009. Reading was examined from school-age (N = 79), drawing and writing 
was examined depending on age. RESULTS: The abilities under examination moved 
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on a wide range. The increase of the mother’s educational level is in signiﬁ cantly posi-
tive relationship with the DS person’s computing (khi2 = 14,314, p = 0,026), drawing/
writing (khi2 = 21,027, p = 0,002) and reading (khi2 = 22,169, p = 0.001) perfor-
mance. It has a favourable effect on the development of the basic self-supporting skills 
(khi2 = 25,571, P < 0.001), and the DS person’s social connections. The majority of 
those lacking friends live with mothers with the lowest qualiﬁ cation (khi2 = 9.799, p 
= 0.02). The level of happiness was measured on a four-grade scale. Owing to a mental 
retardation of medium gravity, surveying was carried out in an indirect way, by 
questioning the parents. The higher parental qualiﬁ cations associated with happier DS 
people (khi2 = 17,344, p = 0.008). The parents’ educational levels are correlated (r = 
0.609, P < 0.001). CONCLUSIONS: More qualiﬁ ed parents provide supportive envi-
ronment rich in stimuli. Higher level of development reduces the DS person’s depen-
dence on others, increases their self-estimation, the level of happiness and through this 
the quality of life improves. It means a smaller burden on the health care system, the 
society and the family. However the professionals taking part in family support must 
be reminded that not every family can perform special child educational tasks inde-
pendently, and they need more intensive family support. 
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OBJECTIVES: Behavioural and psychological symptoms of dementia such as aggres-
siveness, agitation and psychosis are common and very distressful for Alzheimer’s 
disease patients and their caregivers. Their occurrence leads to an increased use of 
psychotropic medications. Memantine treatment has demonstrated signiﬁ cant beneﬁ t 
on these symptoms in the experimental setting of randomized clinical trials. The 
objective of this study was to assess the impact of memantine treatment initiation on 
the use of psychotropic medications in real life practice. METHODS: A retrospective 
prescription claims analysis was conducted using the Quebec provincial public health 
plan (RAMQ) database. Data on medical and pharmaceutical services were obtained 
for the period from January 2004 to March 2009 for a random sample of patients 
who received at least one scripts of memantine. Trends in the proportion of patients 
using psychotropic drugs, antidepressants, neuroleptics, and anti-anxiety agents were 
estimated one year before and after the ﬁ rst prescription of memantine. RESULTS: 
Data were obtained from the RAMQ for a total of 2,007 patients. The study sample 
was 82.2 years old on average (SD = 7.6), with 67.6% of female. Proportion of 
patients using a psychotropic drug in the year preceding the initiation of memantine 
increased by 58.5%, from a proportion of 0.450 to 0.713 while this proportion only 
increased by 3.5% (0.713 to 0.738) in the year following the memantine initiation. 
The increase in proportion of users of antidepressants, neuroleptics, and anti-anxiety 
agents before and after initiation of memantine were 48.3% (0.239 to 0.354) vs. 2.8% 
(0.354 to 0.364), 112.1% (0.219 to 0.465) vs. 1.9% (0.465 to 0.474) and 41.3% 
(0.175 to 0.247) vs. 1.5% (0.247 to 0.250) respectively. CONCLUSIONS: Results of 
this prescription claims analysis indicate that the increasing rate of psychotropic drugs, 
antidepressants, neuroleptics, and anti-anxiety agents use signiﬁ cantly decrease after 
the initiation of memantine.
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OBJECTIVES: Existing assessments of the health related quality of life (HRQoL) in 
patients with multiple sclerosis have focused on persons with the disease. What has 
not been assessed is the extent to which the presence of multiple sclerosis generates 
HRQoL deﬁ cits compared to the general population. METHODS: Data are from the 
internet-based 2008 National Health and Wellness Survey in the UK, France, Spain, 
Italy and Germany. a total of 53,524 respondents completed the survey form, of whom 
308 indicated they had a diagnosis of multiple sclerosis. Respondents completed the 
SF-12 generic HRQoL instrument. The analysis is based on the summary mental 
component scores (MCS), physical component scores (PCS) and health state utilities 
from the SF-6D items derived from the SF-12 instrument. a multivariate analysis (using 
ordinary least squares) was undertaken with the MCS, PCS and SF-6D utilities as 
dependent variables. The independent variables included a binary variable for the 
presence/absence of multiple sclerosis, socio-demographic characteristics, health risk 
factors (e.g., body mass index), country dummy variables and the Charlson Comorbid-
ity Index (CCI). RESULTS: Persons reporting multiple sclerosis had substantially 
lower PCS scores (32.19 vs. 48.66; t = 24.60); MCS scores (39.78 vs. 46.53; t = 10.18) 
and utility scores (0.57 vs. 0.72; t = 23.57). In the multivariate modeling, the deﬁ cit 
associated with the presence of multiple sclerosis was substantially greater than any 
other independent variable in the PCS (−12.07; 95% CI: −14.02 to −10.12) and utility 
models (−0.11; 95% CI: −0.13 to −0.09). The utility decrement in the SF-6D model 
attributed to multiple sclerosis far outweighed the utility deﬁ cits attributable to the 
other independent variables. CONCLUSIONS: Compared to the non-multiple sclero-
sis population, there are substantial HRQoL deﬁ cits associated with the diagnosis of 
multiple sclerosis. These deﬁ cits are substantial and far outweigh those attributable 
to socio-demographic characteristics, health risk factors and the presence of 
comorbidities.
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OBJECTIVES: Management of drug-resistant epileptic patients includes different sur-
gical alternatives. The target patient (i.e. resistant to at least 2 anti-epileptic drugs) 
may undergo neurosurgery or Vagal Nerve Stimulation (VNS). Scope of this work 
was to estimate hospital costs for neurosurgery and VNS and compare with Regional 
funding. METHODS: Investigated phases were: Non-Invasive Diagnostics-NID, 
Invasive-ID, Neurosurgery Intervention-NI or VNS-I, FollowUP-FUP, in 6 referral 
centres. Average/patient cost was estimated by microcosting; resource consumption 
by questionnaire; unit costs valued by full hospital costs (staff, operating-room, hos-
pital-stay), outpatient-tariffs (diagnostics), market-prices (drugs, devices) at 2010 
values. RESULTS: NID-phase: c5070/adult (c3516-c7356) and c4382/child. Ranges 
reﬂ ect variability of hospital-stay and staff time; 79% of total cost is due to diagnos-
tics. DI-phase costs c15,900/adult (37%) and c16,261/child (44%). The cost range 
for adults (c14,098-c17,702) reﬂ ects variability of invasive video-EEG protocols. 
Regional funding is under-remunerative. Considering individual procedures, video-
EEG costs c3,406/adult (cost driver: staff workload); invasive-video-EEG c34,790 
(driver: electrodes). For children, video-EEG costs c3,063 and invasive-video-EEG 
c27,619; lower values are due to higher seizures frequency and shorter duration of 
recordings. Neurosurgery intervention cost is c16,230/adult and c18,894/child. For 
adults, variability (c14,730-c18,513) depends on the duration of intervention, number 
and cost of staffs. Intervention cost is similar in the three Regions and hospital imbal-
ance is the result of under-funding by regional tariffs. VNS insertion cost is c24,543/
adult (c3,518 for the intervention). Under-remuneration by tariffs is conﬁ rmed, even 
considering regional extra-tariffs for the device. Global treatment path for an adult 
(NID + intervention + FUP 5°yrs) amounts to c23,571-NI and c33,373-VNSI; for a 
child c20,066-NI. Regional data: Lombardy, c23,571-NI and c32,244-VNSI, for 
Lazio c25,571-NI and c34,176-VNSI, for Emilia Romagna c22,886-NI and c34,871-
VNSI. CONCLUSIONS: Funding of the management of resistant epilepsies in the 
target patient appears insufﬁ cient to cover costs actually incurred by Italian hospitals, 
irrespective of organization and Regional funding. 
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BACKGROUND: Currently, data-access barriers exist throughout key European 
health-technology assessment countries, including Sweden. Patient registries are of 
limited use due to frequent lapses in data integrity, completeness and limitations 
around access to these data. Additionally, data-protection legislation often prohibits 
the use of existing data from providers and insurance funds. These limitations hinder 
the development of longitudinal health-technology assessments required to evaluate 
the cost-effectiveness of new and existing therapeutics. OBJECTIVES: To explore the 
opportunities and limitations of applying non-local, longitudinal, patient-level treat-
ment and outcomes data to the Swedish environment. METHODS: A large, longitu-
dinal, patient-level treatment and outcomes data set (>55 million US patients from 
>90 health insurance plans) from the USA was used to create a sample of patients 
with multiple sclerosis who were undergoing treatment with disease-modifying drugs. 
Patient outcomes were evaluated with regard to the extent to which patients were 
adherent to therapy. Based on adherence levels, patient tendency to use incremental 
health care system resources was assessed. Adaptation to the local Swedish environ-
ment was performed by incorporating or acknowledging customary aspects of the 
Dental and Pharmaceutical Beneﬁ ts Board (Tandvårds-och läkemedelsförmånsverket) 
cost-beneﬁ t analysis. Costs of outcomes, speciﬁ cally interventions as a result of non-
adherence, were based on Swedish cost-estimates from prior independent research. 
CONCLUSIONS: When performing a cost-effectiveness analysis, incorporation of 
patient-level data from another country invokes caveats on the results, including dif-
ferences in access to care, cultural attitudes and social beliefs. However, in the absence 
of accessible local data, complete and sufﬁ cient data from another country (e.g., the 
USA) can serve as a surrogate. This may limit the broad acceptance of the study’s 
results; however, it provides quantitatively supported and customized results based 
upon a robust data set, upon which health care decision-makers can derive resource 
allocation and prescribing decisions.
